Issues in the Management of Cancer-Related Thrombocytopenia
November 01, 2002
Drs. Goodnough and DiPersio should be commended for contributing such a well-written, well-referenced, objective, and authoritative review of issues in the management of cancer-related thrombocytopenia. Their article focuses primarily on platelet transfusion risks, rational transfusion thresholds, and potential novel pharmaceutical triumphs. The general lack of large-scale, definitive clinical trials in this field is appreciated and emphasized throughout. Much to my disappointment, the authors seem to have passed on the opportunity to provide the oncology community with any form of evidence-based (or evidence-lacking, as the case may be) and practical guideline for the treatment of thrombocytopenia.